SCHEMBL3659616

SCHEMBL3659616

Cc1ccccc1C(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.58
MME P08473 2/20 0.56
ACE P12821 2/20 0.56
CPA1 P15085 1/20 0.56
ACE2 Q9BYF1 1/20 0.56
ITGB2 P05107 3/20 0.55
ICAM1 P05362 3/20 0.55
ITGAL P20701 3/20 0.55
HRH4 Q9H3N8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
POLB P06746 2/20 0.50
MMP9 P14780 2/20 0.49
ELANE P08246 2/20 0.48
MMP8 P22894 1/20 0.48
MMP14 P50281 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4797956 0.89 HRH4 (0.58) SMN1; SMN2MMEACECPA1ACE2
SCHEMBL3660475 0.87 HRH4 (0.56) SMN1; SMN2MMEACECPA1ACE2
SCHEMBL3656763 0.86 HRH4 (0.55) MMEACECPA1ACE2ITGB2
SCHEMBL21623654 0.85 ITGB2 (0.62) MMEACECPA1ACE2ITGB2
SCHEMBL9461912 0.82 CTNNB1 (0.60) MMEACECPA1ACE2ITGB2
SCHEMBL8674187 0.82 CTNNB1 (0.60) MMEACECPA1ACE2ITGB2
SCHEMBL3662835 0.82 CTNNB1 (0.60) MMEACECPA1ACE2ITGB2
SCHEMBL3659456 0.82 MME (0.56) MMEACECPA1ACE2ITGB2
SCHEMBL9716620 0.81 L3MBTL1 (0.74) SMN1; SMN2MMEACEL3MBTL1
SCHEMBL16993893 0.81 L3MBTL1 (0.74) SMN1; SMN2MMEACEL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
EP-2219600-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2010-08-25 EP disclosed
WO-2009067095-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2009-05-28 WO disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR SMN1; SMN2 3339/4885MME 570/4885ACE 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.